TICKERNERD
Menu
GRIGRIHealthcare · Biotechnology

GRI Stock Forecast: GRI Bio, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$1.82
−3.70% on the day

The 2 Wall Street analysts covering GRI Bio, Inc. hold a median 12-month price target of $19 — +916.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.2M
Ticker Nerd rank
29 / 100
Median analyst target
$19
Analysts covering
2
Revenue$0.0
Operating income−$1.6M
Net income−$1.6M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.0%
1M
+9.0%
YTD
−73.7%
1Y
−96.5%
From 52W high
−97.1%
From 52W low
+31.9%
$1
$63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GRI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GRI Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Revisions
74
Growth
63
Quality
35
Issuance
28
Accruals
23
Momentum
20
Volatility
11
Value
5

Size (97): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GRI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26GRIHigh $27Median $19Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $19High $27

The green dot is the last close — the median target sits +916.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$10
21 Aug 2026Ascendiant CapitalMaintainsBuy—
21 Aug 2026Ascendiant CapitalMaintainsBuy$32 → $27
1 June 2026Ascendiant CapitalMaintainsBuy$40 → $32
1 June 2026Ascendiant CapitalMaintainsBuy—
11 Mar 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
27 May 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
14 Apr 2025HC Wainwright & Co.ReiteratesBuy—
9 Dec 2024HC Wainwright & Co.InitiatesBuy—
5 Dec 2024Ascendiant CapitalMaintainsBuy—
8 Oct 2024Ascendiant CapitalInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GRI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, GRI Bio, Inc. returned −96.5% against +15.9% for the S&P 500, dividends included.

GRI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26GRIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

GRI Bio, Inc. (GRI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
0.7×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−142.0%

Higher than 10% of US stocks

Return on assets
−70.9%

Higher than 5% of US stocks

Dividend yield
104.8%

Higher than 98% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GRI Bio, Inc. (GRI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GRI Bio, Inc. has a market value of $4.2M and an enterprise value of −$6.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$9.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$10.4M.

  • GRI Bio, Inc. spent $1K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 2.2M.

  • Trailing P/E: 0.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 104.82%, paying out 0% of earnings.

  • GRI Bio, Inc. employs 3 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

GRI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GRIGRI Bio, Inc.$4.2M
29
OSRHOSR Health, Inc.$4.1M
—
PMCBPharmaCyte Biotech, Inc.$4.2M
29
EOCNEocene Ltd.$4.0M
32
GOVXGeoVax Labs, Inc.$3.9M
39
MBIOMustang Bio, Inc.$3.9M
13
JUNSJupiter Neurosciences, Inc.$4.5M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GRI Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRI news & analysis

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 14 Sept 2026positive

GRI Bio, Inc. (GRI) was upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects. The upgrade suggests the stock may move higher on this improved outlook.

Why it matters — The upgrade signals increased positive sentiment among analysts about GRI's earnings potential, which GRI watchers would view as a favorable development for the stock.

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

Benzinga · 14 Sept 2026positive

Zacks Investment Research upgraded GRI Bio, Inc. to a Buy rating. The news was reported by Benzinga, which also indicated it was watching GRI Bio.

Why it matters — A bullish analyst upgrade from Zacks may draw increased attention and investor interest in GRI Bio shares.

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GlobeNewsWire · 8 Sept 2026positive

GRI Bio presented new Phase 2a data at ERS 2026 detailing GRI-0621's mechanism of action in idiopathic pulmonary fibrosis (IPF) across nine mechanistic pillars. New whole blood RNA sequencing data identified coordinated changes in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect, and GI protection.

Why it matters — The mechanistic data further substantiates GRI-0621's role in IPF and could strengthen the scientific case for the drug's development.

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GlobeNewsWire · 27 Aug 2026neutral

GRI Bio has been featured in a "Why Now" on-demand video webcast, and the webcast is now available for viewing. The item announces the availability of this video presentation about the company.

Why it matters — GRI watchers would care because this on-demand video webcast offers an accessible presentation about the company for investors and interested parties.

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GlobeNewsWire · 24 Aug 2026positive

GRI Bio announced that three abstracts and an oral presentation featuring data from its Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, held September 5-9, 2026 in Barcelona, Spain. The data highlight lung function, anti-fibrotic biomarkers and favorable tolerability in IPF.

Why it matters — Presentation of late-breaking Phase 2a data at a major respiratory congress gives GRI Bio added scientific visibility and external validation for its lead candidate GRI-0621 in IPF.

FAQ

Frequently asked questions about GRI stock

What is the GRI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering GRI Bio, Inc. have a median 12-month price target of $19, with estimates ranging from $10 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRI stock a buy right now?

Of the 2 analysts covering GRI Bio, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRI Bio, Inc. 29 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRI?

As at 14 Sept 2026, GRI Bio, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will GRI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +916.5% from the last close, and Ticker Nerd's factor model ranks GRI Bio, Inc. 29 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRI stock forecast for 2030?

No analyst covering GRI Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $27 over the next 12 months.

How has GRI stock performed over the past year?

GRI Bio, Inc. returned -96.5% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GRI Bio, Inc. do?

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases.

What is the latest news on GRI?

The most recent item we track (Zacks Investment Research, 14 Sept 2026): "GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?". GRI Bio, Inc. (GRI) was upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects. The upgrade suggests the stock may move higher on this improved outlook.

Company

About GRI Bio, Inc.

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression. Its lead program, GRI-0621, is an oral candidate being developed for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. The company is also advancing GRI-0803 for autoimmune disorders, alongside additional early-stage programs and a proprietary library of compounds that support its research pipeline. Based in La Jolla, California, GRI Bio Inc. operates in the biotechnology sector and concentrates on translating immune-system biology into drug candidates for unmet medical needs in specialty disease areas.

CEO Dr. W. Marc Hertz Ph.D. · 3 employees · United States · https://www.gribio.com